Medical Technology

Search documents
ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED
Globenewswire· 2025-10-10 13:15
PALM BEACH GARDENS, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV) today announced that at the special meeting of ZimVie stockholders held on October 10, 2025, the ZimVie stockholders voted to approve the acquisition of ZimVie by an affiliate of ARCHIMED (the “Merger”) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of July 20, 2025 (the “Merger Agreement”). The parties now expect the Merger to close on October 20, 2025, subject to the satisf ...
BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2025
Prnewswire· 2025-10-09 20:15
9k+ Digital Media Outlets 270k+ Journalists Opted In Media: Investors: Fallon McLoughlin Adam Reiffe Director, Public Relations Vice President, Investor Relations 201.258.0361 201.847.6927        [email protected] [email protected]     SOURCE BD (Becton, Dickinson and Company) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers , /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD ...
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran
Globenewswire· 2025-10-09 20:05
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a nationally recognized healthcare leader and one of Modern Healthcare’s 50 Mo ...
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025
Prnewswire· 2025-10-09 20:05
, /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, November 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 6, 2025. SOURCE Haemonetics Corporation The call can be accessed via teleconference at: Q2 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, par ...
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
Globenewswire· 2025-10-09 20:05
Core Viewpoint - Resmed plans to release its financial and operational results for Q1 of fiscal year 2026 on October 30, 2025, after market close, followed by a management webcast to discuss the results and other relevant information [1]. Group 1: Earnings Release Details - The earnings release will occur on October 30, 2025, after the New York Stock Exchange closes [1]. - A webcast will be hosted by Resmed management to discuss the results and other forward-looking information [1]. - A replay of the earnings webcast will be available on Resmed's investor relations website approximately two hours after the live event [2]. Group 2: Company Overview - Resmed is dedicated to creating innovative health technologies aimed at improving the quality of life for individuals in 140 countries [2]. - The company focuses on AI-powered digital health solutions, cloud-connected devices, and intelligent software to enhance home healthcare [2]. - Resmed envisions a future where individuals can achieve better sleep and breathing through personalized care delivered at home [2].
Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting
Globenewswire· 2025-10-09 15:52
Announcement no. 09/2025Inside information Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. “On behalf of the Board, I want to thank Lars for his unwavering dedication to Coloplast. Through his commitment to the company for close to four decades, ...
Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting
Globenewswire· 2025-10-09 15:52
Announcement no. 09/2025Inside information Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. “On behalf of the Board, I want to thank Lars for his unwavering dedication to Coloplast. Through his commitment to the company for close to four decades, ...
Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions
Prnewswire· 2025-10-09 14:10
TIME Best Inventions honors extraordinary innovations changing lives , /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for people with Parkinson's – has been recognized by TIME on its annual list of Best Inventions. There are over 10 million people living with Parkinson's disease globally,and while there is currently no cure, Medtronic deep brain stimulatio ...
Medical Care Technologies (OTC PINK:MDCE) Advances AI Research to Help Identify Early Health Risks in Skin Cancer, Vision, Wound Care, and Mental Wellness
Accessnewswire· 2025-10-09 13:30
MESA, ARIZONA / ACCESS Newswire / October 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a developer of artificial intelligence-powered preventive health technology, today emphasized the urgent human need driving each vertical of its AI platform - underscoring the global lives lost and affected every year to conditions that may be better managed through earlier detection and awareness. Skin Health Over 60,000 people die from melanoma and other skin cancers each year. ...
Xcelerate, Inc. Announces the Sale of its Majority Interest in ESN Group
Accessnewswire· 2025-10-09 13:10
MAULDIN, SC / ACCESS Newswire / October 9, 2025 / Xcelerate, Inc. (OTC Markets:XCRT) today announced the sale of its majority interest in the ESN Group of companies, including ESN Group, Inc. and California Skin Research, Inc to Noble Labs Holdings, LLC, a company that had previously provided funding and marketing support to ESN Group, Inc. The transaction was completed as an all-cash sale. "We made a decision to divest these assets in order to re-focus our business on our original mission of implementing a ...